BiotechTube

Eltrombopag + Avatrombopag + Standard of care

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Thrombocytopenic Purpura

Conditions

Idiopathic Thrombocytopenic Purpura

Trial Timeline

Mar 26, 2012 → Sep 1, 2013

NCT ID
NCT01433978

About Eltrombopag + Avatrombopag + Standard of care

Eltrombopag + Avatrombopag + Standard of care is a phase 3 stage product being developed by Eisai for Idiopathic Thrombocytopenic Purpura. The current trial status is terminated. This product is registered under clinical trial identifier NCT01433978. Target conditions include Idiopathic Thrombocytopenic Purpura.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01433978Phase 3Terminated

Competing Products

20 competing products in Idiopathic Thrombocytopenic Purpura

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oralEisaiPhase 1
33

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85